@docfettzi @doktorin_mama @Stichtmalkurz @Larinjaaa PICC machen wir nur noch sehr sporadisch (teils aufgrund der Verfügbarkeit, teils aufgrund des CAVA-Trials.) Midlines habe ich DE ehrlich gesagt noch nie gesehen. 🤔 https://t.co/HKfBwEuTHx
Full CAVA trial results published in @TheLancet 👇🏼👍🏼 https://t.co/2VYCuRBKVw
Does a port-a-cath have capacity for an allograft @bigjimaus? Practice changing? Thoughts @Berninini @NCICancer @michyong2 @AbbyPDouglas @victoriahall26 @benwteh @TrubianoJason https://t.co/VxN9yzfHoM (Wish our haem nurses on Twitter - would love their in
Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial https://t.co/5vaYISWrvh
Important study!
A good review of central access catheters and their complications, most notable thrombosis.....LOLTA https://t.co/VCkL5fqxtR
RT @walterthom: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs - The Lancet https://t.co/…
RT @walterthom: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs - The Lancet https://t.co/…
RT @walterthom: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs - The Lancet https://t.co/…
RT @walterthom: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs - The Lancet https://t.co/…
For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs - The Lancet https://t.co/Gxh5rwqJe0 #Safetyfirst #valuelife @VygonGroup #polysite #seesite
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
This is not only "Practice" changing but also "Practicality" changing. Are Portacaths safer than and superior to PICC lines? Also, CAVA, a brilliant name for the review! https://t.co/ilFnRgcx85
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
RT @VivekSubbiah: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access…
For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs 👉🏼Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial @TheLancet @OncoAlert https://t.co/plRt42
RT @GlasgowOncology: Link to the paper https://t.co/k4d830PQzy
Link to the paper https://t.co/k4d830PQzy
全身化学療法を行う際、PICC、トンネル型CVC、CVポートを比較したRCTでポートが良かったという報告。実際の現場でも投与期間をちゃんと考えた上で、長期ならポートを選びますし、1~3カ月程度ならPICCが選択肢に入ります。 https://t.co/bJElvhhpZe
https://t.co/8ubrI4BtUo ポートでしかケモ入れたことなかったので「なんでこんなトライアルが?」と思ったけど、海外では看護師の入れやすさからPICCが増えているそう。結果は予想通りだったけど、海外事情がわかってへーっとなりました。
RT @Pepemomia: Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial https://…
RT @ADiamantop: Proof of common knowledge: ports are better than pics and Hickman lines for chemotherapy. https://t.co/ByFqX9Mf1G
Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial https://t.co/PYIu0leedd
For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs. These findings suggest that most patients receiving SACT for solid tumours should receive a PORT. https://t.co/9kfqS8ya4V @ONcotwITting
Much needed high quality data on how to choose the “right” central venous catheter for cancer patients! @SIO_Central @SIRRFS
RT @NatRevClinOncol: In comparison of complication rates and costs of Hickman-type tunnelled catheters, periph inserted central catheters a…
RT @ADiamantop: Proof of common knowledge: ports are better than pics and Hickman lines for chemotherapy. https://t.co/ByFqX9Mf1G
RT @ADiamantop: Proof of common knowledge: ports are better than pics and Hickman lines for chemotherapy. https://t.co/ByFqX9Mf1G
RT @ADiamantop: Proof of common knowledge: ports are better than pics and Hickman lines for chemotherapy. https://t.co/ByFqX9Mf1G
Central venous access devices for the delivery of systemic anticancer therapy Results of the CAVA study (https://t.co/PEz8YGjQM2) published in @TheLancet https://t.co/LwH8303Rzz
In comparison of complication rates and costs of Hickman-type tunnelled catheters, periph inserted central catheters and totally implanted ports (all used to deliver systemic treatment via central vein), the latter were the most effective and safe https://
RT @ADiamantop: Proof of common knowledge: ports are better than pics and Hickman lines for chemotherapy. https://t.co/ByFqX9Mf1G
RT @ADiamantop: Proof of common knowledge: ports are better than pics and Hickman lines for chemotherapy. https://t.co/ByFqX9Mf1G
Proof of common knowledge: ports are better than pics and Hickman lines for chemotherapy. https://t.co/ByFqX9Mf1G
RT @LindajKelly277: CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, t…
RT @davidantibiotic: Large RCT comparing PORTs vs PICCs vs Hickman in cancer patients - PORTs come out on top https://t.co/CBUEffhs7Q
RT @davidantibiotic: Large RCT comparing PORTs vs PICCs vs Hickman in cancer patients - PORTs come out on top https://t.co/CBUEffhs7Q
Large RCT comparing PORTs vs PICCs vs Hickman in cancer patients - PORTs come out on top https://t.co/CBUEffhs7Q
RT @LindajKelly277: CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, t…
1/ A few days ago @TheLancet published an important paper (RCT) on #vascularaccess for patients with #cancer. Totally implanted ports is the better choice. https://t.co/bdeXDOgbEZ
RT @LindajKelly277: CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, t…
🔽Check out this publication - Dr Roshan Agarwal and colleagues from across the UK have published in The Lancet @NGHnhstrust @UHNNHSGroup #research #nhs #RCT https://t.co/xXTqut6gdF
RT @HEHTAGlasgow: 🔥Hot off the press🔥Results of the CAVA trial in @TheLancet have important implications for patients with cancer who rece…
RT @LindajKelly277: CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, t…
RT @LindajKelly277: CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, t…
RT @LindajKelly277: CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, t…
RT @vygonuk: A great article looking into Hickman-type tunnelled catheters, PICC's and Ports when delivering systemic anticancer treatment…
RT @vygonuk: A great article looking into Hickman-type tunnelled catheters, PICC's and Ports when delivering systemic anticancer treatment…
RT @LindajKelly277: CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, t…
A great article looking into Hickman-type tunnelled catheters, PICC's and Ports when delivering systemic anticancer treatment (SACT) via a central vein.
RT @CRUK_GlasgowCTU: The CAVA study has been published! @UofGMVLS For most patients receiving SACT, PORTs are more effective and safer th…
RT @HEHTAGlasgow: 🔥Hot off the press🔥Results of the CAVA trial in @TheLancet have important implications for patients with cancer who rece…
Clickity-click. https://t.co/AFoOX7Rcrl
RT @LindajKelly277: CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, t…
RT @CRUK_GlasgowCTU: The CAVA study has been published! @UofGMVLS For most patients receiving SACT, PORTs are more effective and safer th…
RT @CRUK_GlasgowCTU: The CAVA study has been published! @UofGMVLS For most patients receiving SACT, PORTs are more effective and safer th…
RT @CRUK_GlasgowCTU: The CAVA study has been published! @UofGMVLS For most patients receiving SACT, PORTs are more effective and safer th…
RT @HEHTAGlasgow: 🔥Hot off the press🔥Results of the CAVA trial in @TheLancet have important implications for patients with cancer who rece…
RT @HEHTAGlasgow: 🔥Hot off the press🔥Results of the CAVA trial in @TheLancet have important implications for patients with cancer who rece…
CVADs for systemic anticancer therapy: (CAVA) a RCT has been published! Conclusion: For most patients receiving SACT, totally implanted ports are more effective and safer than both tunnelled CVCs and PICCs. @vygonuk @JasonRam8 @TraceyJ394 @Lisa_TaylorUK
It only took a few years but CAVA is now published! I loved working on a trial of this scale and I’m delighted to see it in print. https://t.co/zaZseTUfC2
RCT: Central venous access devices (Hickman catheters vs. PICCs vs. PORTs) for the delivery of systemic anticancer therapy – “PORTs are more effective and safer than both Hickman and PICCs” – via @TheLancet https://t.co/PumXg5qqxI News release: https://t
Good study on venous access for oncology pts. Well done Prof John Moss 👏🏻👏🏻. https://t.co/hV53dCvwsC @TraineesBSIR @BSIR_News @cirsesociety @SIRspecialists https://t.co/M9XIAP801O
RT @HEHTAGlasgow: 🔥Hot off the press🔥Results of the CAVA trial in @TheLancet have important implications for patients with cancer who rece…
RT @HEHTAGlasgow: 🔥Hot off the press🔥Results of the CAVA trial in @TheLancet have important implications for patients with cancer who rece…
RT @GarbineLizeaga: [Articles] Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlle…
🔥Hot off the press🔥Results of the CAVA trial in @TheLancet have important implications for patients with cancer who receive long-term chemotherapy, led by Jon Moss & Olivia Wu, with @robheggie1 & Evi Germeni & @CRUK_GlasgowCTU et al. Read it h
[Articles] Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial https://t.co/dIalOxyxMA
[Articles] Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial https://t.co/Br3Sf6SwYl